Skip to main content
Top
Published in: Journal of Clinical Immunology 7/2020

01-10-2020 | Primary Immunodeficiency | Original Article

Novel NCF2 Mutation Causing Chronic Granulomatous Disease

Authors: Idit Lachover Roth, Pazit Salamon, Tal Freund, Yael Ben-David Gadot, Szilvia Baron, Tova Hershkovitz, Irit Shefler, Suhair Hanna, Ronit Confino-Cohen, Lea Bentur, David Hagin

Published in: Journal of Clinical Immunology | Issue 7/2020

Login to get access

Abstract

Chronic granulomatous disease (CGD) is a rare primary immunodeficiency disorder caused by defects in the NADPH oxidase complex. Mutations in NCF2 encoding the cytosolic factor p67phox result in autosomal recessive CGD. We describe three patients with a novel c.855G>C NCF2 mutation presenting with diverse clinical phenotype. Two siblings were heterozygous for the novel mutation and for a previously described exon 8–9 duplication, while a third unrelated patient was homozygous for the novel mutation. Mutation pathogenicity was confirmed by abnormal DHR123 assay and absent p67phox production and by sequencing of cDNA which showed abnormal RNA splicing. Clinically, the homozygous patient presented with suspected early onset interstitial lung disease and NCF2 mutation was found on genetic testing performed in search for surfactant-related defects. The two siblings also had variable presentation with one having history of severe pneumonia, lymphadenitis, and recurrent skin abscesses and the other presenting in his 30s with discoid lupus erythematosus and without significant infectious history. We therefore identified a novel pathogenic NCF2 mutation causing diverse and unusual clinical phenotype.
Appendix
Available only for authorised users
Literature
16.
go back to reference AlKhater SA, Deswarte C, Casanova JL, Bustamante J. A novel variant in the neutrophil cytosolic factor 2 (NCF2) gene results in severe disseminated BCG infectious disease: a clinical report and literature review. Mol Genet Genomic Med. 2020:e1237. https://doi.org/10.1002/mgg3.1237. AlKhater SA, Deswarte C, Casanova JL, Bustamante J. A novel variant in the neutrophil cytosolic factor 2 (NCF2) gene results in severe disseminated BCG infectious disease: a clinical report and literature review. Mol Genet Genomic Med. 2020:e1237. https://​doi.​org/​10.​1002/​mgg3.​1237.
19.
go back to reference Clawson CC, Repine JE. Quantitation of maximal bactericidal capability in human neutrophils. J Lab Clin Med. 1976;88(2):316–27.PubMed Clawson CC, Repine JE. Quantitation of maximal bactericidal capability in human neutrophils. J Lab Clin Med. 1976;88(2):316–27.PubMed
23.
go back to reference Moghtaderi M, Kashef S, Rezaei N. Interstitial lung disease in a patient with chronic granulomatous disease. Iran J Pediatr. 2012;22(1):129–33.PubMedPubMedCentral Moghtaderi M, Kashef S, Rezaei N. Interstitial lung disease in a patient with chronic granulomatous disease. Iran J Pediatr. 2012;22(1):129–33.PubMedPubMedCentral
28.
go back to reference Roos D, van Buul JD, Tool AT, et al. Two CGD families with a hypomorphic mutation in the activation domain of p67(phox). J Clin Cell Immunol. 2014;5(3). Roos D, van Buul JD, Tool AT, et al. Two CGD families with a hypomorphic mutation in the activation domain of p67(phox). J Clin Cell Immunol. 2014;5(3).
Metadata
Title
Novel NCF2 Mutation Causing Chronic Granulomatous Disease
Authors
Idit Lachover Roth
Pazit Salamon
Tal Freund
Yael Ben-David Gadot
Szilvia Baron
Tova Hershkovitz
Irit Shefler
Suhair Hanna
Ronit Confino-Cohen
Lea Bentur
David Hagin
Publication date
01-10-2020
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 7/2020
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-020-00820-8

Other articles of this Issue 7/2020

Journal of Clinical Immunology 7/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine